Validation of olfactory deficit as a biomarker of Alzheimer disease
Conclusions:
Olfactory identification deficit is a useful screening tool for AD-related amnestic disorder, with sensitivity and specificity comparable to other established biomarkers, with benefits such as ease of administration and low cost. Olfactory identification deficit can be utilized to stratify risk of conversion from aMCI to AD and enrich clinical trials of disease-modifying therapy.
Classification of evidence:
This study provides Class III evidence that smell identification (10-item UPSIT subset) accurately identifies patients with amnestic disorders.
Source: Neurology Clinical Practice - Category: Neurology Authors: Woodward, M. R., Amrutkar, C. V., Shah, H. C., Benedict, R. H. B., Rajakrishnan, S., Doody, R. S., Yan, L., Szigeti, K., On behalf of the Texas Alzheimer Research and Care Consortium Tags: Alzheimer's disease, Class III, MCI (mild cognitive impairment) Research Source Type: research
More News: Alzheimer's | Brain | Clinical Trials | Neurology | Stroke | Study | University of Pennsylvania